NASDAQ

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

NEW YORK, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

ContraFect Appoints Lisa Ricciardi as Chief Operating Officer

YONKERS, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...